SAREUM HOLDINGS PLC

Regulatory Filings • Jun 26, 2023

/*<![CDATA[*/ /**/ /**/ /**/ h1{margin-top:9.0pt;margin-right:0cm;margin-bottom:6.0pt;margin-left:35.45pt;text-indent:-35.45pt;font-size:10.0pt;font-family:"Times New Roman","serif";text-transform:uppercase;font-weight:bold;}h2{margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;margin-left:1.0cm;text-indent:-1.0cm;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight:bold;}h3{margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;margin-left:1.0cm;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight:bold;}h4{margin-top:12.0pt;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight:bold;font-style:italic;}h5{margin:0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight:normal;font-style:italic;}h6{margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;margin-left:35.45pt;text-align:justify;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight:normal;text-decoration:underline;}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue } visited{ color: #954F72 } .eu{size:595.3pt 841.9pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.eu{}p.fr{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";text-align:center}span.fs{color: black; font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: bold}span.ft{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}p.fu{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:12.1pt;margin-right:0cm; margin-bottom:12.1pt;margin-left:0cm;text-align:center;line-height:normal; background:white}p.fv{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";text-align:justify}p.fw{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:36.0pt;margin-bottom:.0001pt;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:12.1pt;margin-right:0cm; margin-bottom:12.1pt;margin-left:0cm;text-align:justify;line-height:normal; background:white}p.fx{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:36.0pt;margin-bottom:.0001pt;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:12.1pt;margin-right:0cm; margin-bottom:12.1pt;margin-left:0cm;text-align:justify;line-height:normal; background:white}p.fy{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:36.0pt;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:12.1pt;margin-right:0cm; margin-bottom:12.1pt;margin-left:0cm;text-align:justify;line-height:normal; background:white} span.fz{color:black}span.ax{}p.ga{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:36.0pt;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:12.1pt;margin-right:0cm;margin-bottom: 12.1pt;margin-left:0cm;text-align:justify;line-height:normal;background:white}p.a,li.a,div.a{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";}p.gb{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";text-align:center}span.gc{color: black; font-weight: bold}p.gd{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:12.1pt;margin-right:0cm;margin-bottom: 12.1pt;margin-left:0cm;text-align:justify;line-height:normal;background:white}table.ge{margin-left:-5.4pt;border-collapse:collapse}td.fe{width:286.9pt;padding:0cm 5.4pt 0cm 5.4pt}p.gf{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;line-height:normal} span.gg{font-weight: bold}span.bc{}td.fd{width:142.5pt;padding:0cm 5.4pt 0cm 5.4pt}tr.ez{height:26.15pt}td.fb{width:286.9pt;padding:0cm 5.4pt 0cm 5.4pt; height:26.15pt}span.gh{font-size:12.0pt; font-family:"Times New Roman","serif"}td.fa{width:142.5pt;padding:0cm 5.4pt 0cm 5.4pt; height:26.15pt}p.gi{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:12.1pt;text-align:justify;line-height: normal}p.gj{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:12.1pt;margin-right:0cm;margin-bottom: 12.1pt;margin-left:0cm;text-align:justify;line-height:normal}span.fj{color:black} p.gk{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify} .fr-view-element{font-family: sans-serif;font-size: 12pt;line-height: 140%;padding: 20px;box-sizing: border-box;overflow-x: auto;min-height: 60px;text-align: left;margin-bottom: 10px;width: 837px;} .fr-view-element img{padding: 0 1px;} .fr-view-element .eu{margin: 63.8pt 1.6cm 62.35pt 1.6cm;} .fr-view-element p{font-size: 10pt;} /**/ /**/ /**/ /*]]>*/ National Storage Mechanism | Additional information

RNS Number : 8021D

Sareum Holdings PLC

26 June 2023

Sareum Holdings PLC

("Sareum" or the "Company")

Sareum announces two new granted patents, including first patent specifically for SDC-1801

Cambridge, UK, 26 June 2023 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, today announces that the first patent specifically relating to SDC-1801, its lead TYK2/JAK1 kinase inhibitor, has been granted in China. Further, a patent has been formally granted for SDC-1802 and several analogues in the United States, extending the scope of protection beyond immuno-oncology.

Dr John Reader, Sareum's Chief Scientific Officer, commented: "We're delighted to have the first patent granted for SDC-1801, our lead development programme which recently advanced into a Phase 1a clinical trial in Australia. We look forward to being able to strengthen our intellectual property around this asset in other territories in due course." 

"Separately, we are really pleased to have extended the scope of patent protection for SDC-1802 in the US. Although oncology remains the primary focus of this asset, this bulwarks our intellectual property position and gives us optionality to explore opportunities in other therapeutic areas."

SDC-1801 is a dual TYK2/JAK1 kinase inhibitor being developed as a potential new therapeutic for a range of autoimmune diseases with an initial focus on psoriasis, an autoimmune dermatological condition affecting more than 60 million adults worldwide, with a market size for potential treatments estimated to be worth more than US$30 billion. Sareum recently announced that it has begun dosing healthy subjects in a Phase 1a clinical trial for SDC-1801, in Australia.

The China National Intellectual Property Administration (CNIPA) has officially issued patent number CN113056456B, safeguarding SDC-1801 and medical applications of it in treating inflammatory or immune disorders. This is the first patent grant issued to Sareum for SDC-1801 in any territory. Patent applications in Europe (EP3864009), the US (US2021387981) and other territories are still under review.

SDC-1802 is a TYK2/JAK1 inhibitor being developed for cancer immunotherapy. Sareum continues to work on the translational studies needed to support the development of SDC-1802, defining the optimal cancer application prior to completing toxicology and manufacturing studies.

The United States Patent and Trademark Office (USPTO) has formally granted patent number US 11,673,870 B2 specifically covering the treatment of autoimmune disorders with SDC-1802 and several analogues. While Sareum has previously secured international patents providing comprehensive protection for the compound SDC-1802, this patent extends its scope in the US beyond immuno-oncology.

Further information on our patents can be found on our website at: https://sareum.com/patents/

-Ends-

For further information, please contact: 

Sareum Holdings plc Tim Mitchell, CEO Lauren Williams, Head of Investor Relations	01223 497700 ir@sareum.co.uk
Strand Hanson Limited (Nominated Adviser) James Dance / James Bellman	020 7409 3494
Peel Hunt LLP (Joint Corporate Broker) James Steel / Oliver Duckworth	020 7418 8900
Hybridan LLP (Joint Corporate Broker) Claire Noyce	020 3764 2341
Consilium Strategic Communications (Financial PR) Jessica Hodgson / Davide Salvi / Stella Lempidaki	020 3709 5700

About Sareum

Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases and has entered Phase 1a/b clinical development with an initial focus on psoriasis.

Sareum has an economic interest in SRA737, a clinical-stage Chk1 inhibitor which it originally developed in collaboration with several Cancer Research UK-related organisations. SRA737 has shown promising safety and efficacy in two Phase 1/2 clinical trials.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy.

Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCEAKKDADPDEFA